BOS-318 treatment enhances elexacaftor–tezacaftor–ivacaftor-mediated improvements in airway hydration and mucociliary transport
Selective furin inhibition has the potential to further improve clinical outcomes for all people with CF and offers opportunity as an adjunct to improve responses to currently available CFTR modulator therapies.
Authors
- James Reihill (ORCID: https://orcid.org/0000-0001-8599-5198)
- Lisa Douglas (ORCID: https://orcid.org/0000-0002-9248-5409)
- Lorraine Martin (ORCID: https://orcid.org/0000-0002-1923-0610)
Institutions
- Queen's University Belfast (GB)
Publication Details
- Journal
- ERJ Open Research
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1183/23120541.00445-2024
- Citations
- 1
- Primary Topic
- Cystic Fibrosis Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Boston Pharmaceuticals
- Medical Research Council